United States Government Publishing Office
publisher
pbl
distributor
dst
United States
National Archives and Records Administration
Office of the Federal Register
author
aut
Government Organization
text
government publication
eng
FR
Regulatory Information
2009_register
executive
2009-05-06
article
Prospective Grant of Exclusive License: Development of Therapeutics for Use in Humans To Induce Tolerance for Transplantation and To Treat T cell Lymphoma and Leukemia, Autoimmune Diseases Such as Lupus, and Graft-Versus-Host Disease
Notices
D09002ee1bdd378b2
D09002ee1bdd37952
United States
Department of Health and Human Services
originator
org
United States Government Agency or Subagency
United States
National Institutes of Health
originator
org
United States Government Agency or Subagency
This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in U.S. Patent No. 5,167,956 and PCT Application Serial No. PCT/US92/00813 and foreign equivalents thereof, entitled ``Immunotoxin with in vivo T cell suppressant activity and methods of use'' (HHS Ref. No. E-012-1991/0); U.S. Patent No. 5,725,857 and foreign equivalents thereof, entitled ``Immunotoxin with in vivo T cell suppressant activity and methods of use'' (HHS Ref. No. E-012-1991/2); U.S. Patent No. 5,762,927 and foreign equivalents thereof, entitled ``Immunotoxin with in vivo T cell suppressant activity and methods of use'' (HHS Ref. No. E-012-1991/4); Australian Patent No. 762197 and PCT Application Serial No. PCT/US96/ 05087 and other foreign equivalents thereof, entitled ``Methods of inducing immune tolerance using immunotoxins'' (HHS Ref. No. E-012- 1991/5); U.S. Patent No. 6,103,235 and foreign equivalents thereof and U.S. Patent No. 7,125,553 and foreign equivalents thereof, entitled ``Methods of inducing immune tolerance using immunotoxins'' (HHS Ref. No. E-012-1991/7); Australian Patent No. 766692 entitled ``Novel vectors and expression methods for producing mutant proteins'' (HHS Ref. No. E-043-1997/0); U.S. Patent Application No. 10/566,886 and PCT Application No. PCT/US2004/24786 and foreign equivalents thereof entitled ``Methods for expression and purification of immunotoxins'' (E-043-1997/2); U.S. Patent No. 6,632,928 and PCT Application Serial No. PCT/US98/04303 and foreign equivalents thereof, entitled ``Novel immunotoxins and methods of inducing immune tolerance'' (HHS Ref. No. E-044-1997/0); U.S. Patent Application No. 10/296,085 and PCT Application Serial No. PCT/US01/16125 and foreign equivalents thereof entitled ``Immunotoxin Fusion Proteins and Means for Expression Thereof'' (HHS Ref. No. E-044-1997/1); U.S. Patent No. 7,288,254 and PCT Application Serial No. PCT/US99/08606 and foreign equivalents thereof entitled ``Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation'' (HHS Ref. No. E-059-1998/0); Australian Patent No. 781547 and PCT Application No. PCT/US00/10253 and other foreign equivalents thereof, entitled ``Methods related to combined use of immunotoxins and agents that inhibit dendritic cell maturation'' (HHS Ref. No. E-168-1999/0), to Angimmune LLC which is located in Bethesda, Maryland. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory may be United States, Europe, Canada, Australia, Japan, India, Hong Kong, and Brazil and the field of use may be limited to the treatment of T cell lymphoma and leukemia, autoimmune diseases such as lupus, and complications of transplantation, including graft-versus-host disease, and induction of tolerance for organ, pancreatic islet, and cell transplantation as claimed in the Licensed Patent Rights.
74 FR 20966
https://www.govinfo.gov/app/details/FR-2009-05-06/E9-10480
E9-10480
FR06MY09-84
4140-01-P
https://www.govinfo.gov/app/details/FR-2009-05-06/E9-10480
https://www.govinfo.gov/content/pkg/FR-2009-05-06/html/E9-10480.htm
https://www.govinfo.gov/content/pkg/FR-2009-05-06/pdf/E9-10480.pdf
2 p.
20966
20967
74 FR 20966
Prospective Grant of Exclusive License: Development of Therapeutics for Use in Humans To Induce Tolerance for Transplantation and To Treat T cell Lymphoma and Leukemia, Autoimmune Diseases Such as Lupus, and Graft-Versus-Host Disease; Federal Register Vol. 74, Issue
NOTICE
E9-10480
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
2009-07-06
4140-01-P
E9-10480
Notice.
This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in U.S. Patent No. 5,167,956 and PCT Application Serial No. PCT/US92/00813 and foreign equivalents thereof, entitled ``Immunotoxin with in vivo T cell suppressant activity and methods of use'' (HHS Ref. No. E-012-1991/0); U.S. Patent No. 5,725,857 and foreign equivalents thereof, entitled ``Immunotoxin with in vivo T cell suppressant activity and methods of use'' (HHS Ref. No. E-012-1991/2); U.S. Patent No. 5,762,927 and foreign equivalents thereof, entitled ``Immunotoxin with in vivo T cell suppressant activity and methods of use'' (HHS Ref. No. E-012-1991/4); Australian Patent No. 762197 and PCT Application Serial No. PCT/US96/ 05087 and other foreign equivalents thereof, entitled ``Methods of inducing immune tolerance using immunotoxins'' (HHS Ref. No. E-012- 1991/5); U.S. Patent No. 6,103,235 and foreign equivalents thereof and U.S. Patent No. 7,125,553 and foreign equivalents thereof, entitled ``Methods of inducing immune tolerance using immunotoxins'' (HHS Ref. No. E-012-1991/7); Australian Patent No. 766692 entitled ``Novel vectors and expression methods for producing mutant proteins'' (HHS Ref. No. E-043-1997/0); U.S. Patent Application No. 10/566,886 and PCT Application No. PCT/US2004/24786 and foreign equivalents thereof entitled ``Methods for expression and purification of immunotoxins'' (E-043-1997/2); U.S. Patent No. 6,632,928 and PCT Application Serial No. PCT/US98/04303 and foreign equivalents thereof, entitled ``Novel immunotoxins and methods of inducing immune tolerance'' (HHS Ref. No. E-044-1997/0); U.S. Patent Application No. 10/296,085 and PCT Application Serial No. PCT/US01/16125 and foreign equivalents thereof entitled ``Immunotoxin Fusion Proteins and Means for Expression Thereof'' (HHS Ref. No. E-044-1997/1); U.S. Patent No. 7,288,254 and PCT Application Serial No. PCT/US99/08606 and foreign equivalents thereof entitled ``Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation'' (HHS Ref. No. E-059-1998/0); Australian Patent No. 781547 and PCT Application No. PCT/US00/10253 and other foreign equivalents thereof, entitled ``Methods related to combined use of immunotoxins and agents that inhibit dendritic cell maturation'' (HHS Ref. No. E-168-1999/0), to Angimmune LLC which is located in Bethesda, Maryland. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory may be United States, Europe, Canada, Australia, Japan, India, Hong Kong, and Brazil and the field of use may be limited to the treatment of T cell lymphoma and leukemia, autoimmune diseases such as lupus, and complications of transplantation, including graft-versus-host disease, and induction of tolerance for organ, pancreatic islet, and cell transplantation as claimed in the Licensed Patent Rights.
Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before July 6, 2009 will be considered.
Prospective Grant of Exclusive License:
Development of Therapeutics for Use in Humans to Induce Tolerance for Transplantation and to Treat T cell Lymphoma and Leukemia, etc.
,
bishse@mail.nih.gov
Federal Register
Vol. 74, no. 86
Office of the Federal Register, National Archives and Records Administration
2009-05-06
continuing
daily
deposited
born digital
388 p.
Table of Contents:
AE 2.7:
GS 4.107:
AE 2.106:
KF70.A2
https://www.govinfo.gov/app/details/FR-2009-05-06
P0b002ee180024d0a
0097-6326
0042-1219
0364-1406
769-004-00000-9
000582072
f:FR06MY09
https://www.govinfo.gov/app/details/FR-2009-05-06
https://www.govinfo.gov/content/pkg/FR-2009-05-06/pdf/FR-2009-05-06.pdf
https://www.govinfo.gov/content/pkg/FR-2009-05-06/xml/FR-2009-05-06.xml
fdlp
20865
21244
DGPO
2009-05-06
2023-05-01
FR-2009-05-06
machine generated
eng
FR
FR-2009-05-06
74
86